



ASLAN announces a global license agreement with Ammirall for LAS186323 in rheumatoid arthritis

Singapore (21 May 2012) – ASLAN Pharmaceuticals Pte Ltd today announced that global rights to Ammirall's DHODH inhibitor, LAS186323, currently in Phase 1 development for rheumatoid arthritis, have been granted to ASLAN Pharmaceuticals.

Under the agreement, ASLAN will fund and develop LAS186323 to the end of Phase 2 through a development program conducted in the Asia-Pacific region. Upon achievement of proof of concept, ASLAN will identify a global partner for phase 3 development and commercialisation. Financial terms were not disclosed.

"Ammirall has a long history of innovative drug discovery and development and has generated a number of important compounds such as the anti-inflammatory agent aceclofenac, the anti-allergic drug ebastine and the anti-migraine almotriptan" said Dr Mark McHale, ASLAN's Chief Scientific Officer. "While there are several therapies available for rheumatoid arthritis today, physicians and patients continue to look for safer, more effective and more accessible therapies."

"We are very pleased to have a collaboration like this with ASLAN on Ammirall's early stage asset LAS186323. ASLAN has an experienced team and unique model that can leverage its high quality, innovative and efficient clinical development capabilities to continue generating value on the compound while Ammirall focuses on its core R&D strategy" commented Bertil Lindmark, CSO, Executive Director R&D of Ammirall.

About LAS186323

LAS186323 is a novel potent and selective inhibitor of the DHODH enzyme that has shown in vitro anti-proliferative activity in several cellular models and good in vivo efficacy following oral administration. LAS186323 is a second generation DHODH inhibitor that exhibited no signs of hepatotoxicity or hypertension in laboratory animals. In a single ascending dose study in healthy volunteers, linear pharmacokinetics have been observed with the absence of adverse effects. ASLAN will continue the clinical development of LAS186323 in rheumatoid arthritis.

About Ammirall

Ammirall is an international pharmaceutical company based on innovation and committed to health. Headquartered in Barcelona, it researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people's health and wellbeing. Ammirall focuses its research resources on respiratory, gastrointestinal, dermatology and pain. Ammirall's products are currently present in over 70 countries in the five continents. It has direct presence in Europe and Mexico through 12 affiliates.

For further information please visit the website at: www.almirall.com.

About ASLAN

ASLAN Pharmaceuticals is an Asia enabled pharmaceutical company that develops novel medicines for global markets, headquartered in Singapore. ASLAN licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases, and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. ASLAN will partner with pharmaceutical companies for late phase global development and commercialisation.

For more information, please visit www.aslanpharma.com

ASLAN Pharmaceuticals
Sean Wong, +65 62224235
media@aslanpharma.com